WatchGov

119th Congress

S. 5265

USTRx Act

  1. Introduced
  2. In committee
  3. Passed Senate
  4. Passed House
  5. To President
  6. Became law
Sponsor
Tim Sheehy(R-MT)
Introduced
Aug 5, 2026
Policy area
Foreign Trade and International Finance
Committees
Senate Committee on Finance
Official text
Introduced in Senate · Congress.gov page

Cosponsors (2)

Original cosponsors (2)

Summary

Summary by the Congressional Research Service· describes the “Introduced in Senate” version

Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers. The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States. The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.

Roll-call votes

No recorded votes on this bill.

Actions